SCHEMBL7180598

SCHEMBL7180598

Cc1cccc(Cl)c1P(=O)(C(=O)c1c(Cl)cccc1Cl)C(=S)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
PTK2B Q14289 1/20 0.36
TYK2 P29597 1/20 0.36
LMNA P02545 3/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
HTT P42858 1/20 0.36
EPHX1 P07099 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
KMT2A Q03164 1/20 0.34
FABP3 P05413 1/20 0.34
FABP4 P15090 1/20 0.34
KDM4E B2RXH2 1/20 0.34
LCK P06239 2/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175915 0.96 TYK2 (0.39) MAPTPTK2BTYK2LMNAALDH1A1
SCHEMBL7188241 0.95 FABP3 (0.37) MAPTPTK2BTYK2LMNAALDH1A1
SCHEMBL7186800 0.90 LMNA (0.40) MAPTLMNAALDH1A1HTTRAB9A
SCHEMBL7189054 0.90 FABP4 (0.38) MAPTPTK2BALDH1A1GAAHTT
SCHEMBL7183362 0.88 ALDH1A1 (0.35) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL7187974 0.88 FABP4 (0.38) ALDH1A1GAAHTTNPC1RAB9A
SCHEMBL7182217 0.88 MAPT (0.39) MAPTPTK2BTYK2LMNAALDH1A1
SCHEMBL7174859 0.87 RORC (0.39) MAPTTYK2LMNAALDH1A1GAA
SCHEMBL7177894 0.87 ALDH1A1 (0.36) MAPTLMNAALDH1A1GAAHTT
SCHEMBL7184511 0.84 ABCG2 (0.39) MAPTALDH1A1HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885PTK2B 1875/4885TYK2 1285/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885PTK2B 2406/4885TYK2 1333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.